The unrecognized prevalence of chronic kidney disease in diabetes

Middleton, Rachel; Foley, Robert N.; Hegarty, Janet; Cheung, Chi-Ngai; McElduff, Patrick; Gibson, John M.; Kalra, Philip A.; O’Donoghue, Dónal; New, John P.

doi:10.1093/ndt/gfi163

Cited by 145 publications

(101 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar prevalence was obtained in KEEP Mexico [21] as well as in Japan [22]. In two other investigations involving adult patients with diabetes, pathological albuminuria was found in 20.4% to 48.6% and reduced eGFR in 27.5% and 38% [23,24]. However, several studies showed that 10-25% patients with DM1 and DM2 had a non-albuminuric pathway to renal impairment [6,25,26].…”

Section: Discussionsupporting

confidence: 75%

Classification of patients at risk for chronic kidney disease by use of eGFR and albuminuria

Seferović¹,

Ležaić

2015

Biomedicinska istraž.

View full text Add to dashboard Cite

SummaryIntroduction. Screening for chronic kidney disease (CKD) has been advised in high-risk populations. However, data on the prevalence of early asymptomatic stages vary and depend on the definition of CKD. In the present study subjects at risk for CKD (patients with diabetes mellitus type 2-DM2, with hypertension and older than 60 years without diabetes and hypertension) were classified in categories defined by eGFR and albuminuria staging system.

show abstract

Section: Discussionsupporting

confidence: 75%

Classification of patients at risk for chronic kidney disease by use of eGFR and albuminuria

Seferović¹,

Ležaić

2015

Biomedicinska istraž.

View full text Add to dashboard Cite

show abstract

“…33 In two other studies examining adult patients with diabetes, albuminuria was found in 20.4-48.6% and reduced eGFR in 27.5 and 38%. 34,35 Moreover, Barrios et al 36 found GFR less than 60 mL/min/1.73 m 2 in 24.6% of patients with hypertension and chronic ischemic heart disease. It should be underlined that all these studies where a high prevalence of CKD in persons at risk of CKD was found, including our study, showed that most or even all patients with detected markers for CKD denied any knowledge of their kidney disease.…”

Section: Discussionmentioning

confidence: 99%

Screening of a Population at Risk of Chronic Kidney Disease: Analysis of Factors Associated with Low eGFR and Microalbuminuria

Ležaić¹,

Dimković²,

Peković³

et al. 2011

Renal Failure

View full text Add to dashboard Cite

Background and objective: Numerous screenings of chronic kidney disease (CKD) have been performed all over the world. This screening study was undertaken with the aim of estimating the prevalence of low glomerular filtration rate (eGFR) and microalbuminuria (MAU) and/or proteinuria in a population at risk for CKD and to detect factors associated with these CKD markers. Materials and methods: This cross-sectional study included 1617 patients without previously known kidney disease who came for regular check-ups to their general practitioners in 13 Belgrade health centers over a 3-month period. Patients selected were as follows: 1316 with hypertension, 208 with type 2 diabetes, and 93 older than 60 years without hypertension or diabetes. Screening included a questionnaire, blood pressure measurement, single MAU dipstick measurement (Micral-test ® strip) and proteinuria and GFR estimation by Modification of Diet in Renal Disease. Results: MAU was found in 419 (25.9%) patients, proteinuria in 163 (10.1%), and eGFR < 60 mL/min/1.73 m 2 in 370 (22.9%). Multivariate logistic regression analysis revealed that female gender, age, duration of hypertension, and smoking were associated with eGFR. Male gender, hypertension, treatment with angiotensinconverting enzyme inhibitors, proteinuria, and systolic blood pressure were associated with MAU. Conclusions: High prevalence of MAU/proteinuria and reduced eGFR were found in high-risk persons for CKD. Besides nonmodifiable, significant modifiable factors for MAU were use of angiotensin-converting enzyme inhibitors and strict regulation of hypertension and the factor for reduced eGFR was smoking.

show abstract

“…In addition to the increased risk of CKD in patients with diabetes, evidence suggests that the rate of progression of CKD is usually faster among diabetic than non-diabetic individuals 1) . Despite these observations, CKD -particularly in diabetic patients -is often underdiagnosed and undertreated 8,[14][15][16][17][18] . For example, in the interim analysis of the Atorvastatin Lipid Lowering Assessment Survey in Patients with Hypercholesterolemia (ALWAYS) trial 18) , a post-marketing surveillance study of atorvastatin in Japan, the primary physician diagnosed 8% of the cases as having CKD.…”

Section: Lipid Targets and Treatment Options For Patients With Ckd Anmentioning

confidence: 99%

Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience

Koya

Campese

2013

JAT

View full text Add to dashboard Cite

Diabetes is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in developed nations, including Japan and the United States. Japan has the unenviable distinction of having one of the world's highest rates of dialysis: in 2011, there were over 300,000 dialysis patients (2,383 per million people), with diabetic patients accounting for almost half of all incident cases. Concomitance of CKD and diabetes predicts a greater risk of cardiovascular disease (CVD) than either condition in isolation. Hence, appropriate management of modifiable cardiovascular (CV) risk factors, including dyslipidemia, is paramount in this high-risk group. The United States and Japan have distinct approaches to cholesterol management, with more stringent therapeutic targets for lipid control advocated in US guidelines. However, upward trends in cholesterol levels and coronary heart disease incidence in Japan may provide justification for more intensive CV risk factor management strategies by Japanese physicians to achieve maximum benefit. Attainment of recommended lipid goals in Japan is poor, particularly in patients with diabetes and/or CKD in whom CV risk factors are often undertreated. Statin therapy has been shown to be safe and effective in reducing CV risk in patients with diabetes and/or CKD stages 1-5. Moreover, statins may impart a renoprotective effect by preventing or delaying progressive loss of kidney function. This review summarizes evidence from studies in Western and Japanese populations to highlight the CV and renal benefits of lipid-lowering agents in CKD patients, including those with diabetes. J Atheroscler

show abstract

The unrecognized prevalence of chronic kidney disease in diabetes

Cited by 145 publications

References 16 publications

Classification of patients at risk for chronic kidney disease by use of eGFR and albuminuria

Classification of patients at risk for chronic kidney disease by use of eGFR and albuminuria

Screening of a Population at Risk of Chronic Kidney Disease: Analysis of Factors Associated with Low eGFR and Microalbuminuria

Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience

Contact Info

Product

Resources

About